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The aqueous extraction of the sesquiterpene lactone xanthatin from Xanthium spinosum L. favours the 35 
conversion of xanthinin (1) to xanthatin (2) via the loss of acetic acid. The cytotoxic (Hep-G2 and 36 
L1210 human cell lines) and antiviral activities of isolated xanthatin are established. This natural 37 
compound shows significant cytotoxicity against the Hep-G2 cell line and our experimental results 38 
reveal its strong anti-angiogenesis capacity in vitro. The structure of xanthatin is determined by 39 






1. INTRODUCTION 46 
 47 
The plant Xanthium spinosum L. (Asteraceae, Compositae) has been the object of a large number of 48 
chemical and biological studies. It is used in traditional medicine in different countries [1,2]. Extracts 49 
from X. spinosum L. contain a mixture of compounds such as: b-sitosterol, quercetin and other 50 
flavonoids such as pendulin, iocein, centaurin and patuletin 3-O-glucoside [3]. Moreover, it contains 51 
xanthanolide sesquiterpene lactones such as: xanthinin (1), xanthatin (2), stizolicin (3) and solstitialin 52 
(4) [4] (Fig. 1). 53 
The chloroform extracts of X. spinosum aerial parts are reported to be used to treat hydrophobia 54 
treatment, rabies and intermittent fever [5] as well as for the treatment of diarrhoea and cancer [3,6]. The 55 
isolated sesquiterpene lactones xanthinin (1), stizolicin (3) and solstitialin (4)were tested for antitumor 56 
action in vitro on two types of tumors: L-1210 leukemia and P-388 leukemia [7]. 57 
The major constituents of X. spinosum dichloromethane extraction showed antiviral properties [8,9] 58 
whereas the methanol extracts of Xanthium strumarium leaves have been used to treat inflammatory 59 
diseases such as rheumatoid arthritis [10] and have also showed anticancer activity with IC50 ¼ 3.0, 2.2 60 
and 1.5 mg/Ml against MCF-7, A431 and HepG2 cell respectively [11]. The main responsible 61 
constituents of the inhibition of the proliferation of human tumor cells in vitro were the xanthanolides 8-62 
epixanthatin and 8-epi-xanthatin epoxide [12]. 63 
Xanthanolides are a class of sesquiterpenoids isolated primarily from Xanthium (family Asteraceae) 64 
[13]. The chemical structures of numerous xanthanolides are well documented, though much more is 65 
known of the biological data of the extracts than of their synthetic preparation. In general, the 66 
xanthanolides present a gbutirolactone fused to a seven-membered ring. Depending of this fusion, the 67 
xanthanolides can be divided into two structural types: the cis- (8-epi-xanthatin, xanthanolide 68 
numbering) and the transfused lactones (Fig. 1). Xanthatin (2) was first isolated from Xanthium 69 
pennsylvanicum by J. E. Little and co-workers [14] and its structure was established by Geissman et al. 70 
[4,15]. The latter group suggested the possibility that xanthatin could be formed from xanthinin by 71 
dehydration during isolation, particularly during purification by column chromatography. The first total 72 
synthesis of a xanth  anolide, specifically ( )-dihydroxanthatin, was reported by Morken with sequential 73 
ruthenium-catalysed metathesis reactions [16]. Recently, Shishido and co-workers reported the 74 
enantiocontrolled  total synthesis of ( )-xanthatin from an optically pure bicyclic lactone [17]. 75 
Sesquiterpene lactones exhibit interesting biological activities not exploited by the pharmaceutical 76 
industry and have also attracted considerable attention from organic chemists interested in synthetic 77 
routes to produce these natural products and for their structural characterization. 78 
We use an extraction process to obtain 2 from X. spinosum and evaluate its anticancer, antiviral and 79 
anti-angiogenic activities. Its structure was established by 1H NMR, 13C NMR, IR and MS, and 80 
confirmed by X-ray crystallography for the first time (The resulting crystal structure has been deposited 81 
at the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 755280) 82 
[18]. 83 
84 
2. Material and methods 85 
 86 
2.1. General methods 87 
 88 
Melting points were obtained on an MFB-595010M Gallenkamp apparatus in open capillary tubes and 89 
are uncorrected. IR spectra were obtained using an FTIR PerkineElmer 1600 Infrared 90 
Spectrophotometer.  Only noteworthy IR absorptions are listed (cm 1). 1H and 13C NMR spectra were 91 
recorded on a Varian Gemini-200 (200 and 50.3 MHz respectively) or Varian Gemini-300 (300 and 75.5 92 
MHz) Instrument using CDCl3 as solvent and tetramethylsilane as internal standard or (CD3)2CO. 93 
Other 1H NMR spectra and heterocorrelation 1He13C (HMQC and HMBC) experiments were recorded 94 
on a Varian VXR-500 (500 MHz). Assignments were established by DEPT, HMBC and HMQC. Mass 95 
spectrawere recorded on a ThermoFinnigan Trace DSQ equipped with an APCI or ESI source. High-96 
resolution ESI-MS were measured on an LC/MSD-TOF mass spectrometer. Internal reference masses 97 
m/z ¼ 121.050873 (purine), 922.009798 (HP-0921), data acquisition and processing were performed 98 
with Xcalibur 1.3 software. Column chromatography was performed with silica gel (E. Merck, 70e230 99 
mesh). Reactions were monitored by TLC using 0.25 mm silica gel 60 F254 plates (E. Merck), detection 100 
was achieved by the absorbance of UV light (254 nm and 366 nm) or spraying with different reagents 101 
(sulfuric acid-10% w/w ceric sulfate followed by  heating 5 min at 80e110 C depending of the used 102 
reagent) and the Rf values was obtained from the analytical TLC. Microanalysis was determined on a 103 
Carlo Erbae1106 analyser. All reagents were of commercially quality or were purified before use. 104 
Organic solvents were of analytical grade or were purified by standard procedures. Commercial solvents 105 
were purchased from SigmaeAldrich.  106 
 107 
2.1.1. Materials 108 
DMEM (Dulbecco's modified Eagle's medium, Sigma, St. Louis MO, USA), PBS (phosphate saline 109 
buffer, Sigma, St. Louis MO, USA), DMSO (dimethylsulfoxide, Sigma, St. Louis MO, USA), FCS 110 
(fetal calf serum, Gibco-BRL, Eggenstein, Germany), penicillin/streptomycin (Gibco-BRL, Eggenstein, 111 
Germany), culture well-plates (Techno Plastic Products, Trasadingen, Switzerland), MTT (3-(4,5-112 
dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma, St. Louis MO, USA). 113 
 114 
2.1.2. Drugs 115 
The product extracted was previously dissolved in 10 mg/mL in DMSO. In the treatment, this solution 116 





2.2. Plant material 122 
Aerial fresh young plants of X. spinosum (Asteraceae family) were collected in June and July at 123 
Barcelona coastline (Spain) and were authenticated by comparison with a sample of this specie 124 
deposited at the Institut Botanic, CSIC-Ajuntament de Barcelona (Spain). The species were air-dried and 125 
ground. 126 
 127 
2.3. Extraction and isolation 128 
A dry residue (100 g) of X. spinosum L. was soaked in 300 mL of water. The mixture was heated at 100 129 
  C in an ultrasound bath for 30 min. Then, the residuewas filtered under suction and the filtrate was 130 
extracted with ethyl ether: ethyl acetate, 1:1, in 3 portions. The solid residue was discarded and the 131 
combined organic extracts were dried over Na2SO4, filtered and the solvents removed under vacuum. 132 
The residue obtained from the evaporation of the solvents was satisfactorily purified by column 133 
chromatography using a column 50 cm high place with a diameter of 2.5 cm which was packed with 134 
slurry of silica gel and hexane. The residue was dissolved in the minimum amount necessary of the 135 
dichloromethane and applied with a pipette to the top of the silica bed. The column was eluted with a 136 
hexane-ethyl acetate mixture of increasing polarity, as the solvent system. The solvent gradient used 137 
ranged from 100% hexane to 100% ethyl acetate and fractions of 15 mL were collected. The fractions 138 
were collected manually and those with similar TLC profiles were pooled. Xanthatin was eluted with 139 
hexane-ethyl acetate, 1:1, and caffeic acid was obtained by elution with ethyl acetate 100%. 140 
The xanthatin extracted from X. spinosum is a white solid that is soluble in chloroform, 141 
dichloromethane, methanol and acetone; and slightly soluble in cold water. The xanthatin obtained was 142 
purified by column chromatography using silica gel to 99.9% purity before the analytical and biological 143 
tests. 144 
Xanthatin: CA: 26791-73-1. IUPAC name: 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-((E)-3-145 
oxo-1-buten-1-yl)-(3aR,7S,8aS,(E))-2H-cyclohepta[b]furan-2-one. The structure was established by 146 
spectral methods and confirmed by X-ray diffraction. Analytical data was also compared with the 147 
bibliographic reported data [4].    White needles (methanol); mp 111e113 C (111e112 C) [4], 148 
 114.5e115 C (Merck Index 2006, compound number 10058); Rf 0.39, silica gel 60 F254, hexane:ethyl 149 
 acetate (1:1);½a 20 D    ¼ 20  (c ¼ 0.12 g in 5 mL of CH2Cl2) [4], IR (KBr) ymax 1763 (C]O), 1683 150 
(C]O), 1586 (C]CH), 976 (CeO), 896 (C]CeC) cm-1; EM (IE) (m/z,  %), 246 (Mþ, 15), 231 (M 15, 18), 151 
204 (47), 175 (75), 123 (100), 91 (C7H7þ, 97), 77 (C6H5þ, 90), 53 (C4H5þ, 94); anal. C 73.44%, H 152 






2.5. In vitro cytotoxic activity assay 159 
 160 
2.5.1. Cell culture 161 
This study was performed on human hepatic cellular carcinoma Hep-G2 cells (ECACC n. 85011430). 162 
The cells were cultured in DMEM supplemented with 2 mM glutamine, 10% heat-inactivated FCS (fetal 163 
calf serum), 10,000 units/mL of penicillin and 10 mg/mL of streptomycin. The cells were maintained at 164 
 37 C in vitro as monolayer cultures placed in 100 cm diameter culture well-plates in a 95% humidified 165 
atmosphere with 5% CO2. After confluence, the cells were subcultured following trypsinization and 166 
centrifugation every 3e4 days, depending on the number of cell. Cell viability for the different 167 
experiments and cell counts were assessed by trypan blue (0.04%) exclusion dye using a 168 
haemocytometer. The drugs to be tested were added to cultures one day after seeding the cells to ensure 169 
uniform attachment of the cells at the beginning of the experiments [19]. 170 
 171 
2.5.2. MTT assay 172 
To determine of antiproliferative activity on tell cell lines, the viability of the cultured cells was 173 
determined by assaying the reduction of MTT: the cells with metabolic capacity reduce MTT to 174 
formazan. The assay was performed by a variation of the method described by Mosmann [20], 5103 175 
cells/well were seeded in 96 well  plates with 200 mL medium. After 24 h incubation at 37 C, to ensure 176 
cell adherence, the mediumwas removed and new medium was added containing different 177 
concentrations of the compounds.  The cells were incubated for 24 h at 37 C in a humidified incubator 178 
with 5% CO2. After incubation, MTT was added to a final concentration of 0.5 mg/mL in the medium. 179 
The cells were incubated for  1 h at 37 C. Then 100 mL of DMSO was added per well to dissolve the 180 
formazan crystals. Relative cell viability was obtained by measuring the absorbance on an ELISA plate 181 
reader (Tecan Sunrise MR20-301, TECAN Austria) at 550 nm. The absorbance is directly proportional 182 
to the level of cell proliferation or viability [19]. The IC50 value was determined from a doseeresponse 183 
curve using 4 different concentrations. Each concentration was analysed in triplicate. 184 
 185 
2.6. In vitro antiviral activity assay 186 
 187 
The antiviral activity of xanthatin was evaluated against the following viruses: herpes simplex virus type 188 
1 (HSV-1); herpes simplex virus type 2 (HSV-2); varicela-zoster virus (VZV); vesicular stomatitis virus; 189 
vaccinia virus; feline corona virus (FIPV); feline herpes virus; coxsackie virus B4; respiratory syncytial 190 
virus; influenza A H1N1; influenza A H3N2; influenza B; parainfluenza-3 virus; repvirus-1; sindbis 191 
virus and punta toro virus 192 
The anti-virus assay method has been described previously. The antiviral activity was evaluated based 193 
on the inhibition of virus induced cytopathicity or plaque formation in human embryonic lung (HEL) 194 
fibroblasts, African green monkey cells (VERO), human epithelial cells (HeLa) or in Crandell-Rees 195 
feline kidney cells (CRFK). 196 
Human embryonic lung (HEL) fibroblasts were grown in 96-well microtitre plates infected with the 197 
corresponding virus and incubated. After a 2 h incubation period, the residual virus was removed and 198 
the infected cells were further incubated with the medium containing different concentrations of 199 
xanthatin (in duplicate). After 6 days, the cell cultures were examined microscopically. Antiviral activity 200 
was expressed as the 50% effective concentration required to reduce viral plaque formation after 5 days 201 
by 50% compared to untreated controls. 202 
 203 
2.7. In vitro angiogenesis activity assay 204 
 205 
Freshly cut aortic rings obtained from 5- to 10-week-old Fischer 344 male rats were embedded in 206 
collagen gels and transferred to 16mmwells each containing 0.5 mL of MCDB 131 as described [21]. 207 
Controls were treated with vehicle alone (0.2% dimethylsulfoxide (DMSO)). The microvascular growth 208 
curves are characteristic for each gel [22e25]. Experiments included minimum three to four observations 209 
per data point and were repeated at least two times. 210 
 211 
2.8. Statistical analysis 212 
 213 
Statistical calculations were carried out with the Microsoft Office Excel 3.0. Results are expressed as the 214 
mean ± S.E.M. of minimum 5 independents experiments. Student's t-test was used for statistical 215 
analyses and P values <0.05 were considered to be significant. 216 
217 
3. RESULTS AND DISCUSSION 218 
 219 
3.1. Chemistry 220 
 221 
Xanthatin has previously been extracted from several genera of Xanthium and other genera of the 222 
Asteraceae family using organic solvents (acetone [15], dichloromethane, methanol [12] and others) but 223 
not by aqueous reflux. Therefore, Geissman and co-workers converted xanthinin to xanthatin by 224 
treatment with sodium acetate in ethanol [15]. In this work, to determine the principal constituents of 225 
infusions of X. spinosum, extraction was performed by boiling the dry extract in water for a short period 226 
of time, assisted by ultrasound. The crude residue represented 24% of the dry weight of fresh plants of 227 
X. spinosum used as the starting material. This simple process requiring little time (30 min), mild 228 
temperatures  (<100 C) and soft frequencies (ranging from 20 to 50 kHz) is very efficient. These 229 
conditions favour the conversion of xanthinin (1) to xanthatin (2), and this would explain the formation 230 
of xanthatin (2) and no detection of xanthinin (1) or its derivatives. 231 
Caffeic acid was obtained as 1.12e1.21% of the dry plant weight. From each sample of 100 g of plant 232 
powder 1.1e1.3 g of xanthatin (2) was obtained. This represents 1.1e1.3% of the dry plant weight or 233 
0.9e1.04% of the fresh plant weight (quantities higher than those published in other works). An infusion 234 
with 1.5 g of dry plant contains approximately 16.5e19.5 mg of xanthatin (2) and 16.8e18.2 mg of 235 
caffeic acid. With this extraction procedure, no other sesquiterpenes were isolated. 236 
For the structural study 1H NMR, 13C NMR and 2D 1He13CHeteronuclear shift correlation spectra 237 
were used. The relative stereochemistry of xanthatin (2) was determined for the first time by the X-ray 238 
diffraction (3aR*, 7S*, 8aS*). Thus, whereas H-3a is in the a position, H-8a is in the b-position. The 239 
configuration of double bonds C5eC6 and C10-C20 is (E). Five olefinic protons were observed in the 240 
1H NMR: two trans-coupled protons at 6.20 and 7.08 ppm (in CDCl3) with a J ¼ 16 Hz, corresponding 241 
to H-10 and H-20, two coupled protons at 5.50 and 6.21 ppm with a J ¼ 3.4 Hz corresponding to the 242 
exocyclic methylene and a methyne group at 6.27 ppm corresponding to the H-5. The HMQC and 243 
HMBC analysis confirmed the position of methyl and methylene groups and also the presence of a,b-244 
unsaturated ketone at C-6 position of the heterocyclic ring. 245 
The presence of the g-butirolactone condensed with a cycloheptene ring, the position of the side chain 246 
and the a-exocyclic methylene group at C-3 position were confirmed from the singlecrystal X-ray 247 
crystallographic analysis (Fig. 2). All the analytical data were verified by the comparison with these 248 
reported in the literature [4,15]. From the structural evidence, the main compound isolated was 249 





3.2. Pharmacology 255 
 256 
The cytotoxicity of xanthatin (2) in Hep-G2 (hepatocellular carcinoma, human) and L1210 (mouse 257 
lymphocytic leukemia) cell cultures was evaluated. Their antiviral properties and capacity to inhibit 258 
angiogenesis were also tested. 259 
 260 
3.2.1. Cell growth inhibition 261 
The cytotoxic properties of Xanthium (Asteraceae) are well known, but the in vitro cytotoxicity of 262 
isolated xanthatin (2) has been less studied [26,27]. Inhibition of cell proliferation was observed 263 
following treatment of Hep-G2 and L1210 cell lines with xanthatin. The concentration required for 50% 264 
inhibition of growth, IC50 at 24 h on Hep-G2 cells was 49.0 ± 1.2 mM (Fig. 3) and 12.3 ± 0.9 mM on 265 
L1210 cells. The relative percentage of cell proliferation was calculated by considering untreated control 266 
cells after 24 h as 100% cell proliferation. 267 
 268 
3.2.2. Antiviral activity 269 
Xanthatin (2) showed inhibitory activity against a wide variety of virus including Herpes simplex, 270 
vaccinia and vesicular stomatitis in HEL cell cultures, feline corona, feline herpes in CRFK cell cultures, 271 
vesicular stomatitis virus, coxsackie virus B4 and respiratory syncytial virus in HeLa cell cultures. The 272 
results were compared to these obtained for the reference compounds brivudin, ribavirin, ciclofovir and 273 
ganciclovir [28]. 274 
Xanthatin lacked inhibitory activity against the three types of influenza tested (influenza A H1N1, 275 
Influenza A H3N2 and Influenza B) (Table 1). Xanthatin showed pronounced cytotoxic activity against 276 
MDCK cell cultures of influenza and also against Vero cell cultures with minimal cytotoxic 277 
concentrations (MCCs) of 4 and >20 mM respectively (Table 2). 278 
This natural compound possesses a relatively high toxicity. The therapeutic index (CC50/EC50) is <5 279 
for several virus tested and MCCs values where in the same range as their EC50 values. 280 
 281 
3.2.3. Anti-angiogenesis activity 282 
The formation of neovessels from the endothelium of pre-existing vessels is an essential part of 283 
embryonic development and, tissue repair and plays a critical role in the progression of several fatal 284 
diseases including cancer, diabetes, and rheumatoid arthritis [29]. The vasculature density is correlated 285 
with the malignancy and aggressiveness of tumor. Angiogenesis favours the growth of solid tumors as 286 
well as their invasion and metastasis [30,31]. Clinical results for the first generation of anti-angiogenic 287 
drugs demonstrated no additional clinical benefit compared with the classic antitumor treatments. 288 
Consequently, more research will be needed to obtain more promising angiogenesis inhibitors. The rat 289 
aortic ring explants model in three-dimensional collagen gel matrixes and the HUVEC capillary tube 290 
formation assay on a Matrigel synthetic basement membrane matrix are commonly used in vitro 291 
angiogenesis systems. The anti-angiogenic response to xanthatin was evaluated in vitro in rat aorta ring 292 
explant cultures over 14- days in the presence of exogenous VEGF stimulation. Doserelated inhibitory 293 
effects on microvessel growth were observed from 0.03 mMto 10 mM(Fig. 4) and 0.3 nM to 3 294 
mMxanthatin (Fig. 5). 295 
Xanthatin displayed significant inhibition (IC50 ¼ 0.028 ± 0.001 mM) of capillary tube formation (by 296 
measuring the area in mm2 with regard to the concentration of xanthatin tested) relative to untreated 297 
control. This anti-angiogenic response was comparable to the effect of paclitaxel (IC50 ¼ 0.002 mM) 298 
which is considered to be one of the best antiangiogenic drugs. Xanthatin and paclitaxel showed similar 299 
behaviour. Thus, the anti-angiogenic effects of xanthatin and paclitaxel prevailed at low doses, while at 300 
high doses both showed cytotoxic activity. Moreover, the inhibition of angiogenesis is not 301 
dosedependent for either compound. The inhibition of angiogenesis has not previously been studied 302 
either for xanthatin or for xanthium extract, and these properties could be used in the treatment of solid 303 
tumor. 304 
 305 
4. CONCLUSIONS 306 
 307 
In conclusion, although xanthatin has been isolated from several 308 
species in the Asteraceae family, this is the first report of its fast 309 
aqueous extraction from X. spinosum and also the first X-ray 310 
confirmation of the structure proposed by Geissman and coworkers. The procedure allows xanthinin to 311 
be transformed into xanthatin and both the performance and the purity of this compound to be increased. 312 
Xanthatin shows cytotoxicity against L1210 and Hep-G2 cell lines. Excellent inhibition of angiogenesis 313 
was observed; comparable to that of paclitaxel. Also, xanthatin shows inhibitory activity against several 314 
viruses, but with a therapeutic index <5. 315 
Xanthatin can be isolated from X. spinosum in small quantities and total synthesis is often difficult; but 316 
the isolated compound could be used as a lead compound for the development of xanthatin derivatives 317 
with therapeutic effects. The present study suggests that xanthatin plays an important role in 318 
angiogenesis inhibition, which is promising for tumor treatment. Further research is required to elucidate 319 
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.417 
Legends to figures 418 
 419 
Figure 1. Sesquiterpene lactones. 420 
 421 
Figure 2.. Chemical structure and ORTEP of xanthatin. 422 
 423 
Figure 3. Cytotoxic activity of xanthatin (IC50) on Hep-G2 (left) and L1210 cells (right). 424 
 425 
Figure 4. Inhibition of angiogenesis in rat aortic ring in response to anti-angiogenic treatment 426 
(xanthatin) at concentrations of 0.03e10 mM after 14 days. Paclitaxel was tested in the same experiment 427 
to provide comparative data. 428 
 429 










































Table 4. Supramolecular interactions C–H...X (X5Cl or C) parameters for complexes 1 and 2 472 
 473 
 474 
